ImmunityBio Inc. Common Stock vs Planet Labs — how do they compare? ImmunityBio Inc. Common Stock trades at $10 (market cap $10.33B), while Planet Labs trades at $17.44 (market cap $6.46B). The key difference: ImmunityBio Inc. Common Stock is the larger of the two by market cap, and ImmunityBio Inc. Common Stock is trading nearer its 52-week high, Planet Labs nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ImmunityBio Inc. Common Stock for 0 Days and Planet Labs for 4 Days on average.
| IBRX | PL | |
|---|---|---|
Market Cap | $10.33B | $6.46B |
Volume | 11,745,198 | 10,188,839 |
Sector | Health | Industrials |
52-Week High | $11.55 | $51.40 |
52-Week Low | $1.98 | $11.16 |
Typical Hold Time | 0 Days | 4 Days |
Enterprise Value | $10.79B | $6.09B |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →Planet Labs operates Earth-imaging satellites and provides geospatial data products. Its imagery and analytics help governments and businesses monitor changes across the planet.
Read more on PL →